PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), which are targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 pathway, with/without chemotherapy, have been developed for treatment of metastatic NSCLC [2, 10].